#### Impact of health systems interventions in primary health 1

#### settings on type 2 diabetes care and health outcomes 2

#### among adults in West Africa: a systematic review protocol 3

4	
5	
6	Eugene Paa Kofi Bondzie <sup>1*</sup> , Yasmin Jahan <sup>2¶</sup> , Dina Balabanova <sup>2¶</sup> , Tony Danso-Appiah <sup>4</sup> , Tolib Mirzoev <sup>2&amp;</sup> ,
7	Edward Antwi <sup>3</sup> , Irene Ayepong <sup>1&amp;</sup>
8	
9	
10	<sup>1</sup> Ghana College of Physicians and Surgeons, Accra, Ghana
11	<sup>2</sup> London School of Hygiene and Tropical Medicine, London, United Kingdom
12	<sup>3</sup> Ghana Health Service, Accra, Ghana
13	<sup>4</sup> University of Ghana, Legon, Ghana
14	
15	
16	*Corresponding Author
17	Email: <u>eugenebondzie@gmail.com</u> (EPKB)
18	
19	
20	<sup>¶</sup> These authors contributed equally to this work

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

21 <sup>&</sup>These authors also contributed equally to this work

- 22
- 23

# 24 Funding

- 25 This research was conducted as part of the health research on strengthening of capacity for non-
- 26 communicable diseases (NCD) control in West Africa (Stop NCDs project) commissioned by the
- 27 National institute for health Research (NHIR), global health research centres: research and
- 28 institutional capacity strengthening In NCDs Call 1 (grant number- 203246). The views expressed in
- 29 this publication are those of the author(s) and not necessarily those of the NIHR or the UK
- 30 government.
- 31
- 32
- 33

## 34 Competing interest

- 35 None declared
- 36

## 37 Registration details

38 Prospero registration number is CRD42023439897

- 40

## 41 Abstract

42	Type 2 diabetes remains a major global public health challenge particularly in the African region.
43	Though evidence exists on pharmacological agents and non-pharmacological interventions in
44	maintaining blood glucose concentration, the health systems ability in meeting patients' needs may
45	be inadequate. However, the management of non-communicable diseases particularly diabetes,
46	have been postulated to depend largely on functioning health systems. This systematic review will
47	therefore, summarize the current evidence on existing health systems interventions in primary
48	health settings for type 2 diabetes care and health outcomes in West Africa and would explore the
49	impact of these system-level interventions on service availability, accessibility and quality, as well as
50	individualized outcomes such as glycemic control, disease awareness and treatment adherence.
51	The review will be conducted in accordance with the reporting guidance provided in the Preferred
52	Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P). The health system
53	framework by Witter et al, 2019 will guide the system-level interventions and the search strategy to
54	be explored in this review. This framework was designed to integrate the six building blocks of the
55	World health's organization (WHO) health systems framework and delineates how they work
56	synergistically to improve specific health outcomes. We will search the following databases PubMed,
57	Google scholar and Cumulated Index to Nursing and Allied Health Literature (CINAHL) between
58	January 2000 to June 2023 and Car.info from inception to June 2023. The Cochrane Collaboration
59	tool for assessing Risk of Bias will be implemented on each included study to assess for risk of bias.
60	We will conduct a narrative synthesis and make comparisons across findings using Excel generated
61	tables.
<b>C2</b>	

62 The main limitation of this study is that we are likely to miss out on studies not conducted in English63 or French since our search would be conducted in English and French only.

In Conclusion, this systematic review will outline the existing system-level interventions that aim to or already improve type 2 diabetes services in primary health facilities in West Africa and would allow for strengthening and co-production of successful interventions that can be generalized to the entire sub-region.

68

69

## 70 Introduction

71 Type 2 diabetes, formerly known as adult-onset diabetes, is a major global public health problem(1). 72 It is defined as a form of diabetes mellitus that is characterized by high blood glucose, insulin 73 resistance and a relative lack of insulin and it manifests with symptoms of increased thirst, frequent 74 urination, weight loss and sometimes increased hunger(2). Long term complications from high blood 75 sugar includes ischemic heart disease, retinopathy, nephropathy and limb amputations(3). 76 Maintaining blood glucose concentration is highly essential to prevent severe complications(4). Until 77 recently, it was thought to affect adults who were middle-aged or older but recent trends have 78 shown an increase incidence in young people(5). Reports from epidemiological studies suggest that 79 adults aged 20-79 years living with type 2 diabetes are about 10.5% of the world's population(6). In 80 Sub-Saharan Africa, the disease is estimated to increase by 129% by 2045 due to an increase in 81 population and rapid urbanization(6). This phenomenon is worsened by the large number of 82 undiagnosed individuals living with the disease. According to published reports from the 83 international diabetes federation (IDF) Atlas, people with undiagnosed diabetes in the African region represent the highest comparative proportions worldwide, currently at 54% and expected to 84 85 increase by 2045(6). Consequently, the number of diabetes related death was reported at 416,000 86 compared with 111,100 deaths in Europe. These disproportionate number reflect the poor 87 structures at various levels of the primary care management of non-communicable diseases in the

88 African region(7,8). Evidence exists on the effectiveness of pharmacological and non-

pharmacological treatment for type 2 diabetes(9,10,11) but the health systems ability in meeting
patients' needs may be inadequate(2,7).

91 The management and control of type 2 diabetes is largely dependent on health systems(12). The 92 treatment of diabetes is challenging because health systems are designed for short-term care rather 93 than long-term care of people(13). A healthcare system is an organization of people, institutions, 94 and resources that delivers health care services to meet the health needs of target populations(14). 95 Effective health systems can improve the delivery of diabetes care and promote patient's access and 96 utilization of quality services including access to medications, health facilities and specialists, with an 97 overall impact on glycemic control and other associated outcomes (e.g., adherence, morbidity and 98 mortality etc.)(14,15,16).

99 A previous systematic review was conducted by Nuche-Berenguer, et al (17) on the readiness of

100 health systems in tackling diabetes in Sub-Saharan Africa, with part of the review focused on

101 evaluating pilot projects, targeted at enhancing the capacity of health systems in diabetes care.

102 However, this review was conducted six years ago, at a time when health system interventions

103 towards type 2 diabetes were now evolving in most Sub-Saharan African countries especially West-

104 African countries. Thus, the majority of the studies identified in that review were based-off eastern

and southern Africa and the pooled findings may not be necessarily generalizable in recent times to

106 other parts of Africa. The review also could not synthesize the impact of the interventions on

107 glycemic control due to the scarcity of relevant papers.

However, studies have been conducted between that period and the present to determine the impact of health system strengthening interventions on glycemic control. These include strategies aimed at improving the training and distribution of healthcare personnel, improving patient followup appointments, improving medicines distribution, and decentralizing services to patients at the primary-care level etc. Also, diversity exists between the sub-populations, their economic growth,

health facility distribution, general disease burden and political structures. Thus, it will be importantto determine which interventions have been practical in the West African sub population.

115 According to the World Health Organization (WHO), health systems interventions can be defined as 116 any array of initiatives that improves one or more of the functions of the health systems and that 117 leads to better health through improvements in access, coverage, quality or efficiency(18). Chee et 118 al, proposed that these initiatives should aim at permanently making the systems function better, 119 not just filling gaps or supporting the systems to produce better short-term outcomes. They further 120 submit that an intervention to strengthen the health system should go beyond providing inputs and 121 apply to more than one building block, citing the six core components of health systems identified by 122 the WHO.

123 For the purposes of this review, the health system interventions framework by Witter et al(18) in

124 2019 would guide the system-level interventions to be explored in this review (S1 Fig). This

125 framework was designed to integrate the six building blocks of the WHO health systems framework

126 (14). The framework by Witter et al, describes mechanisms of change within six health system blocks

127 (governance, financing, infrastructure, workforce, supply chain and information), describes the

128 implementation process goals and outlines the final desired outcomes. Interventions that promote

any of these domains of the health system or across integration of the domains, have been proven

to have significant impact on the outcome of a health condition (non-communicable disease) in the

131 African setting(19).

132 This systematic review will summarize the recent evidence on health system interventions

implemented in primary care facilities to improve the accessibility, delivery and quality of healthcare

134 for type 2 diabetes in West Africa; and will explore the impact and effectiveness of these

135 interventions on overall glycemic control, disease awareness and treatment adherence.

136

#### 137 S1 Fig. Health systems interventions framework (Modified from the health systems strengthening

#### 138 framework by Witter et al(18))

139	[]		
140	Health system inputs	Machanisms of Change	Outcomes
141	nearth system inputs	Mechanishis of Change	Outcomes
142			
143	Service delivery Health Workforce	Applying a change or an intervention in each of	Quality, safe services available and accessible
144	Supply chain Health information	the health system inputs either singly or in	Responsiveness Efficiency (e.g.,
145	Financing	combination. For example, training	good glycemic control)
146	Governance	and skills building, changed incentives,	interventions
147		social dialogue	prevalence
148		health provider-patient),	health outcomes and
149		times, improving and maintain logistics.	equity Social and financial risk
150		organizational culture	
151		administrative	
152		governance and financing processes), structural reforms	
153			

154

#### **Review question** 155

- 156 This systematic review aims to answer the question;
- 157 How do health systems interventions influence care and health outcomes of type 2 diabetes in
- 158 primary health settings among adults in West Africa?

159

**Objectives** 160

### 161 General

- 162 To identify the health system interventions in primary health settings that influence the accessibility,
- 163 delivery and quality of type 2 diabetes care among adults in West Africa.

### 164 Specific

- 165 1. To synthesize the evidence on the effectiveness of these system-level interventions on glycemic
- 166 control, awareness and treatment adherence.
- 167 2. To explore the impact of these system-level interventions on any associated health outcomes
- 168 (e.g., service availability, service utilization etc.)

#### 169

170

## 171 Methods

172	This systematic review will follow the reporting guidance provided in the Preferred Reporting Items

173 for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) statement (20) (S1 Checklist)

174

### 175 Criteria for considering studies for this review

176

### 177 **PICOS eligibility (S1 Table)**

### 178 **Types of studies**

- We will include studies with randomised controlled trials (RCTs) trials, clinical control trials
- 180 (CCTs) and quasi-experimental designs
- Observational studies including cross-sectional studies, cohort studies, case-control studies

182 and case series will be excluded

- Gray literature (e.g., books, commentary, dissertations, conference proceedings, modeling
- and simulation studies) will also be excluded.

### 185 Types of participants and setting

- The participants to be covered in this review will be adults aged 18 years or more in West
- 187 Africa with a diagnosis of type 2 diabetes.
- Studies conducted in a primary health facility setting (community health and planning
- 189 services (CHPS) compound, health center, district hospital/clinic) will be eligible
- Studies on gestational diabetes (since its natural history varies significantly from type 2
- 191 diabetes(21)), and type 1 diabetes will be excluded
- Also, studies that evaluated both type 1 diabetes and type 2 diabetes together will be
- 193 excluded, if we cannot extract findings from the group with type 2 diabetes.
- Studies that explored diabetic care interventions conducted solely in the community setting
- 195 without describing collaboration with health facilities will be excluded.
- 196 **Types of Interventions**
- 197 We will define the health system interventions using the modification from the framework by Witter
- 198 et al(18) and a descriptive approach employed by Byinringiro et al(19)
- Studies would be eligible if the interventions address the following health system inputs
- 200 (i.e., Service delivery, health workforce, supply chain, health information systems, financing
- 201 governance) in the following ways;
- Service delivery. WHO defines service delivery as the activities that directly provide safe,
- 203 effective, and high-quality health services to patients in need. Thus, we will consider the
- 204 studies to enhance the capacity of this aspect of the health systems if the target of the
- 205 intervention was to enhance patients access to health services for diabetes like screening,
- 206 treatment, and follow-up, either through equitable distribution of care services, reduction

207	of out-patient waiting time, revision of time allocated for services, or integrating the
208	delivery of diabetes care with other established health services like HIV or TB.
209 •	Health workforce. The interventions of interest in this aspect of the health systems would
210	focus on healthcare providers who manage diabetes. The interventions include strategies to
211	increase the number of providers, improve provider knowledge and implementation of
212	diabetes management guidelines, address provider decision support systems, promote
213	teamwork, and institute task sharing and/or task shifting strategies to include providers
214	who do not normally perform certain diabetes management tasks like prescription of
215	medications.
216 •	Supply chain. In this aspect of the health systems, we will include studies with interventions
217	that target enhancing the capacity of the procurement systems to ensure the availability of
218	anti-diabetic medications, availability and maintenance of calibrated glucometers,
219	availability of consumables to conduct screening and other diabetes investigations, patient
220	follow-up technologies like use of short message systems, and treatment guidelines.
221 •	Health information systems. We will consider interventions to enhance the capacity of
222	health information systems if they studied an element of the process of patient data
223	collection, analysis, sharing, and use to improve outcomes of interest. Interventions that
224	explore the use of patient registries and information between patients and providers and
225	among providers will be included
226 •	Financing. The financing aspect of the health systems, as defined in the WHO building
227	blocks, has the most significant relevance on the national macro-level health systems. It
228	also plays an impact on the micro-level health systems' service delivery and patients'
229	outcomes. We will consider studies where the interventions aimed at reducing patients' out
230	of pocket spending or funding of diabetes care at the health facilities through national and
231	sub-national spending on health insurance premiums, or other relevant financial reliefs.

232	•	Governance. This aspect has direct and indirect associations with the other five building
233		blocks of the health systems. We will consider studies to address leadership and
234		governance if the intervention promote a facility's leadership awareness of the burden of
235		poor diabetes management, or if the intervention uses strategic planning and
236		implementation of national diabetes management protocols in a health care facility,
237		explores the accountability measures at the health facility, applies regular performance
238		appraisal and planning for improvement, integrates supportive mentorship to lower
239		primary health facilities, institutes a patient feedback collection and response system, or
240		examines the leadership allocation of funds for diabetes management. We will also
241		consider interventions where leadership joins or collaborate with other health facilities or
242		local/international/national/private/non-governmental organizations to manage diabetes.
243	•	Only studies that piloted interventions with a minimum follow-up period of six months will
244		be eligible.
245	•	We will exclude studies that examined only patient-level or community-level
246		lifestyle/behavioral changes or other non-conventional medical/non-medical interventions
247		for diabetes management.
248	Comp	parison
249	Interve	ntion groups would be compared with corresponding groups where there were no strategies
250	to enha	ance any of the health systems inputs with respect to diabetes care.
251	Outco	ome
252	We wil	l evaluate the impact of the interventions on any of the following outcomes:
253	•	Good glycemic control. Defined by the American college of endocrinologists as glycated
254		hemoglobin (HbA1c %) levels below 7% or fasting blood sugar levels below 110mg/dl (6.1
255		mmol/l)(4).

- Diabetes awareness. Defined as persons with clinically measured diabetes (either with
- 257 HbA1c or fasting blood sugar levels), who have been diagnosed by a physician or health
- 258 provider with appropriate training to make a diagnosis.
- Treatment Adherence. Defined as consistently complying with a treatment plan (either an
- 260 oral anti-diabetic or insulin, or a life style plan) as prescribed/advised/implemented by a
- 261 health care provider (22).
- Type 2 diabetes service availability and patient's access to these services

#### 263 Language

- 264 We will include articles published in English or French. These two are the main languages spoken in
- West Africa.
- 266

### 267 S1 Table. PICOS eligibility

Population	Adults aged 18 years or more in West Africa
Intervention	System-level interventions that targets the health system inputs in the Witter et al
	health system frame work within primary health facilities
Comparison	Corresponding groups where there were no strategies to enhance any of the health
	systems inputs with respect to diabetes care
Outcome	Main outcome is glycaemic control. Other health outcomes include: awareness,
	treatment adherence, type 2 diabetes services availability and patient access.
Study design	Randomized Controlled Trials (RCTs), Clinical Controlled trials (CCTs), quasi
	experiments

268

269

### 270 Search Strategy

#### 271 Bibliographic databases

- 272 We will search the following databases PubMed, Google scholar and Cumulated Index to Nursing
- and Allied Health Literature (CINAHL) between January 2000 to June 2023 and Car.info from
- inception to June 2023. This time frame is selected to encompass studies that would have likely
- 275 benefited from recent development and improvement in RCTs, CCTs and quasi-experimental studies.
- 276 We will define the search terms for primary health care of diabetes at the facility level by borrowing
- and modifying the search strategy published in a systematic review of health systems interventions
- 278 for hypertension by Byiringiro et al(19) These search terms will likely encompass the primary health
- 279 care practices for diabetes management in our setting of interest.
- 280 The search strategy consists of intersections between the following medical subject headings
- 281 (MeSH); ("Health Services," Delivery of Health care," "Primary Health Care," "Health Facilities,"
- 282 "Health Care Facilities, Manpower, and Services," "Healthcare Financing," "Insurance, Health,
- 283 Reimbursement, "Health Information Systems," "Equipment and Supplies"); and intersected with
- type 2 diabetes ("Diabetes mellitus, type 2," "Glycemic Control," "Diabetes Complications,"
- 285 "Hyperglycemia,") and West African countries ("African, Western"). The full search strategy is
- 286 presented in S2 Table

#### 287 Searching other resources

We will check the bibliographies of all relevant studies to identify other potential publications. The references of any relevant systematic reviews and scoping reviews identified will also be scrutinized for relevant trials.

We will also contact the authors of articles whose full text is not easily accessible after searching through multiple online databases and where there are questions related to the results of the study or trial design, we will seek confirmation on the information that we extract from their studies. In case of no feedback from the authors, the corresponding studies will be excluded. Also, studies that do not measure any of the outcome variables (glycaemic control, adherence, and awareness) will be

- excluded. Where there are duplicates for studies published in more than one paper, the most
- 297 comprehensive one reporting the largest sample size will be considered.

298

### 299 Study selection

- 300 Two reviewers will independently scan the titles and abstracts of all records yielded by the search to
- 301 determine their eligibility for full-text screening and their full articles will be assessed through the
- databases and imported into the <u>Rayyan</u> screening software(22).
- 303 The full text of all potentially eligible articles will be screened and assessed for inclusion into the
- 304 review, by a trained reviewer, using a pre-specified eligibility form based on the inclusion criteria (S3
- 305 Fig). At least one paper will be piloted before the main selection. Disagreements will be resolved
- 306 after reaching a consensus or through discussion with a third reviewer. Neither of the review
- 307 authors will be blind to the authors, institutions or journal titles of potential articles. We will present
- 308 the number of included studies and the number of excluded studies using the PRISMA flow chart (S3

309 Fig)

310

### 311 Data Extraction and management

Two reviewers will independently extract study characteristics and record them on pre-designed forms (S3 Table). The form would first be piloted on two included studies to ensure information is captured in a standard manner. We will extract data from each study on the first author, year of publication, language, study design, setting (country and facility level), health system domain and intervention explored, and outcomes. Disagreements will be resolved in consultation with the third reviewer.

318

### 319 **Dealing with missing Data**

- We will contact the authors of included studies for which data related to study methods, andoutcomes are unclear or missing.
- 322

### **Risk of Bias and quality Assessment of included studies**

- 324 To assess for possible risk of bias in the included studies, we will collect information using the
- 325 Cochrane Collaboration tool for assessing Risk of Bias(23)in a study (S4 Fig). The risk of bias tool
- would be implemented on each study and scored as high, low, or unclear risk (where there is
- 327 insufficient detail reported), for the following domains: random sequence generation (selection
- 328 bias); allocation concealment; blinding of participants and personnel (performance bias); blinding of
- 329 outcome assessment (detection bias); incomplete outcome data (attrition bias); selective reporting
- 330 (reporting bias). These scores would be assigned independently by the two review authors.
- 331 Disagreements would be solved by discussion and consultation with a third reviewer. A table
- 332 representing the risk of bias assessments within and across studies will be computed using
- 333 Cochrane's Review Manager (Version 5.3)
- 334

### 335 Data synthesis and Analysis

We will conduct a narrative synthesis of the health system interventions identified from the studies by creating a table to compare the PICO elements. We will classify the outcomes into the following groups; glycemic control, diabetes awareness and treatment adherence. We will use relative risk to report the effect measures of the interventions on diabetes outcomes and compare them across all included studies. Our findings would be reported using tables generated from Excel.

341

### 342 Assessment of confidence in cumulative estimate

343	The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE)(24) approach
344	will be implemented to assess the quality of the evidence for any of the outcomes. We will report a
345	table on the GRADE evidence profile for the quality of the studies on the following domains: 1) risk
346	of bias 2) inconsistency 3) indirectness 4) imprecision 5) publication bias 6) magnitude of effect 7)
347	residual 8) dose-response 9) overall GRADE quality scored as very low (very uncertain about the
348	estimate of effect), low (further research is very likely to change the estimate of effect, moderate
349	(further research may likely change the estimate of effect), high quality (i.e., further research is very
350	unlikely to change our confidence in the estimate of effect). (S5 Fig)
351	
352	Ethical considerations

Ethical approval will not be needed for this review protocol because data will be extracted frompublished studies and there will be no concerns about privacy.

- 355
- 356

### 357 **Discussion**

358 By the end of this review, we aim to provide a report on integrated system-level interventions in the

health systems of primary health facilities aimed at improving the delivery and quality of type 2

360 diabetes services as well as patients access to these services. We will further explore effectiveness of

- 361 these interventions on the impact on patients' glycemic control for at least 6 months. We would
- 362 then outline areas of strengths and gaps in already existing interventions for the purposes of health
- 363 policies, co-production of interventions and wide-spread uptake in the entire region.

364

### 365 Strengths and Limitations

- 366 This review will provide valuable insights into the latest health system interventions for the
- 367 management of type 2 diabetes in West Africa and explore the effect of integrated system-level
- 368 interventions on provision of care for type 2 diabetes. The literature search would be conducted in
- 369 only English and French thus we are likely to miss out on relevant studies in other languages. E.g.,
- 370 Portuguese.
- 371

### 372 **Dissemination plans**

- 373 Results from this review would be disseminated through academic journals, policy briefs, stake
- 374 holder and intervention co-production workshops.
- 375

### **Dealing with Amendments**

- 377 The corresponding author, Eugene Paa Kofi Bondzie, is responsible for any amendments and update
- 378 of this review protocol.
- 379
- 380

## 381 Authors' contributions

- 382 Study protocol conceptualization and design: Eugene Paa Kofi Bondzie (EPKB), Yasmin Jahan (YJ),
- 383 Dina Balabanova (DB).
- 384 Supervision: Irene Agyepong (IA), Edward Antwi (ED), Tolib Mirzoev (TM), Tony Danso-Appiah (TDA).
- 385 Validation: Dina Balabanova (DB), Irene Agyepong (IA), Tolib Mirzoev (TM).
- 386 Original draft writing: Eugene Paa Kofi Bondzie (EPKB)
- 387 **Review and editing**: Eugene Paa Kofi Bondzie (EPKB), Yasmin Jahan (EPKB)
- 388
- 389

## 390 Acknowledgements

- 391 We would like to acknowledge Mary Pomaa Agyekum, the librarian who helped in the development
- of the search strategy.
- 393

394

## 395 **References**

- Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet. 2016 Oct 8;388(10053):1545–602.
- Rasooly RS, Akolkar B, Spain LM, Guill MH, Del Vecchio CT, Carroll LE. The National Institute of
   Diabetes and Digestive and Kidney Diseases Central Repositories: A Valuable Resource for
   Nephrology Research. Clin J Am Soc Nephrol. 2015 Apr 7;10(4):710–5.
- 403 3. Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of Diabetes and Diabetes-Related
   404 Complications. Phys Ther. 2008 Nov;88(11):1254–64.
- 4. Bin Rakhis SA, AlDuwayhis NM, Aleid N, AlBarrak AN, Aloraini AA. Glycemic Control for Type 2
  406 Diabetes Mellitus Patients: A Systematic Review. Cureus. 14(6):e26180.
- 407 5. Tfayli H, Arslanian S. Pathophysiology of type 2 diabetes mellitus in youth: the evolving
  408 chameleon. Arq Bras Endocrinol Metabol. 2009 Mar;53(2):165–74.
- 409 6. Home, Resources, diabetes L with, Acknowledgement, FAQs, Contact, et al. IDF Diabetes Atlas
  410 2021 | IDF Diabetes Atlas [Internet]. [cited 2023 Jun 19]. Available from:
  411 https://diabetesatlas.org/atlas/tenth-edition/
- 412 7. Atun R, Gale EAM. The challenge of diabetes in sub-Saharan Africa. The Lancet Diabetes &
  413 Endocrinology. 2015 Sep 1;3(9):675–7.
- 414 8. Gill G. Diabetes in Africa Puzzles and challenges. Indian J Endocrinol Metab. 2014;18(3):249–51.
- Sandholzer-Yilmaz AS, Kroeber ES, Ayele W, Frese T, Kantelhardt EJ, Unverzagt S. Randomised
  controlled trials on prevention, diagnosis and treatment of diabetes in African countries: a
  systematic review. BMJ Open. 2022 May 10;12(5):e050021.
- 418 10. Bekele H, Asefa A, Getachew B, Belete AM. Barriers and Strategies to Lifestyle and Dietary
  419 Pattern Interventions for Prevention and Management of TYPE-2 Diabetes in Africa, Systematic
  420 Review. J Diabetes Res. 2020;2020:7948712.
- 421 11. Raveendran AV, Chacko EC, Pappachan JM. Non-pharmacological Treatment Options in the
   422 Management of Diabetes Mellitus. Eur Endocrinol. 2018 Sep;14(2):31–9.

medRxiv preprint doi: https://doi.org/10.1101/2023.08.31.23294889; this version posted September 1, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

- 423 12. Prenissl J, Jaacks LM, Mohan V, Manne-Goehler J, Davies JI, Awasthi A, et al. Variation in health 424 system performance for managing diabetes among states in India: a cross-sectional study of 425 individuals aged 15 to 49 years. BMC Medicine. 2019 May 13;17(1):92.
- 426 13. Idrees T, Castro-Revoredo IA, Migdal AL, Moreno EM, Umpierrez GE. Update on the 427 management of diabetes in long-term care facilities. BMJ Open Diabetes Res Care. 2022 428 Jul;10(4):e002705.
- 429 14. World Health Organization. Monitoring the building blocks of health systems: a handbook of 430 indicators and their measurement strategies [Internet]. Geneva: World Health Organization; 431 2010 [cited 2023 Mar 16]. Available from: https://apps.who.int/iris/handle/10665/258734
- 432 15. Atun R, Davies JI, Gal EAM, Bärnighausen T, Beran D. Diabetes in sub-Saharan Africa: from 433 clinical care to health policy. 2017;5.
- 434 16. Timpel P, Harst L, Reifegerste D, Weihrauch-Blüher S, Schwarz PEH. What should governments 435 be doing to prevent diabetes throughout the life course? Diabetologia. 2019 Oct 1;62(10):1842-436 53.
- 437 17. Nuche-Berenguer B, Kupfer LE. Readiness of Sub-Saharan Africa Healthcare Systems for the New 438 Pandemic, Diabetes: A Systematic Review. Journal of Diabetes Research. 2018 Feb 18;2018:1– 439 12.
- 440 18. Witter S, Palmer N, Balabanova D, Mounier-Jack S, Martineau T, Klicpera A, et al. Health system 441 strengthening—Reflections on its meaning, assessment, and our state of knowledge. The 442 International Journal of Health Planning and Management. 2019;34(4):e1980–9.
- 443 19. Byiringiro S, Ogungbe O, Commodore-Mensah Y, Adeleye K, Sarfo FS, Himmelfarb CR. Health 444 systems interventions for hypertension management and associated outcomes in Sub-Saharan 445 Africa: A systematic review. PLOS Glob Public Health. 2023;3(6):e0001794.
- 446 20. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 447 statement: an updated guideline for reporting systematic reviews. Systematic Reviews. 2021 448 Mar 29;10(1):89.
- 449 21. Linné Y, Barkeling B, Rössner S. Natural course of gestational diabetes mellitus: long term follow 450 up of women in the SPAWN study. BJOG. 2002 Nov;109(11):1227-31.
- 451 22. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for 452 systematic reviews. Systematic Reviews. 2016 Dec 5;5(1):210.
- 453 23. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane 454 Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011 Oct 18;343:d5928.
- 455 24. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. 456 Rating the quality of evidence. J Clin Epidemiol. 2011 Apr;64(4):401–6.
- 457
- 458

#### **Supporting Information** 459

medRxiv preprint doi: https://doi.org/10.1101/2023.08.31.23294889; this version posted September 1, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

## perpetuity. It is made available under a CC-BY 4.0 International license .

#### S1 Checklist. Prisma-P 2015 checklist 460

- (DOCX) 461
- S2 Table. Search strategy for PubMed 462
- (DOCX) 463
- S2 Fig. Study selection flow chart 464
- (DOCX) 465
- S3 Fig. PRISMA flow chart 466
- (DOCX) 467
- **S3** Table. Data extraction Form 468
- (DOCX) 469
- S4 Fig. Cochrane Risk of Bias Tool 470
- 471 (PDF)
- S5 Fig. The Grading of Recommendations, Assessment, 472
- **Development, and Evaluation (GRADE) Assessment Tool** 473
- (PDF) 474